Your browser doesn't support javascript.
loading
Toward ß-Secretase-1 Inhibitors with Improved Isoform Selectivity.
Johansson, Patrik; Kaspersson, Karin; Gurrell, Ian K; Bäck, Elisabeth; Eketjäll, Susanna; Scott, Clay W; Cebers, Gvido; Thorne, Philip; McKenzie, Michael J; Beaton, Haydn; Davey, Paul; Kolmodin, Karin; Holenz, Jörg; Duggan, Mark E; Budd Haeberlein, Samantha; Bürli, Roland W.
Afiliación
  • Johansson P; Discovery Sciences, IMED Biotech Unit , AstraZeneca , S-43183 Mölndal , Sweden.
  • Kaspersson K; Discovery Sciences, IMED Biotech Unit , AstraZeneca , S-43183 Mölndal , Sweden.
  • Gurrell IK; Neuroscience, IMED Biotech Unit , AstraZeneca , Cambridge CB21 6GH , U.K.
  • Bäck E; Discovery Sciences, IMED Biotech Unit , AstraZeneca , S-43183 Mölndal , Sweden.
  • Eketjäll S; Cardiovascular and Metabolic Diseases, IMED Biotech Unit , AstraZeneca , 141 57 Huddinge , Sweden.
  • Scott CW; Discovery Safety, Drug Safety and Metabolism, IMED Biotech Unit , AstraZeneca , Waltham , Massachusetts 02451 , United States.
  • Cebers G; Neuroscience, IMED Biotech Unit , AstraZeneca , Cambridge CB21 6GH , U.K.
  • Thorne P; Charnwood Molecular , Loughborough LE11 5DA , U.K.
  • McKenzie MJ; Charnwood Molecular , Loughborough LE11 5DA , U.K.
  • Beaton H; Charnwood Molecular , Loughborough LE11 5DA , U.K.
  • Davey P; Oncology Chemistry, IMED Biotech Unit , AstraZeneca , Cambridge CB4 0WG , U.K.
  • Kolmodin K; Sprint Bioscience , 141 57 Huddinge , Sweden.
  • Holenz J; Neuroscience, IMED Biotech Unit , AstraZeneca , Cambridge CB21 6GH , U.K.
  • Duggan ME; Neuroscience, IMED Biotech Unit , AstraZeneca , Cambridge CB21 6GH , U.K.
  • Budd Haeberlein S; Neuroscience, IMED Biotech Unit , AstraZeneca , Cambridge CB21 6GH , U.K.
  • Bürli RW; Neuroscience, IMED Biotech Unit , AstraZeneca , Cambridge CB21 6GH , U.K.
J Med Chem ; 61(8): 3491-3502, 2018 04 26.
Article en En | MEDLINE | ID: mdl-29617572
ABSTRACT
BACE1 is responsible for the first step in APP proteolysis, leading to toxic Aß production, and has been indicated to play a key role in the pathogenesis of Alzheimer's disease. The related isoform BACE2 is thought to be involved in processing of the pigment cell-specific melanocyte protein. To avoid potential effects on pigmentation, we investigated the feasibility for developing isoform-selective BACE1 inhibitors. Cocrystal structures of 47 compounds were analyzed and clustered according to their selectivity profiles. Selective BACE1 inhibitors were found to exhibit two distinct conformational features proximal to the flap and the S3 subpocket. Several new molecules were designed and tested to make use of this observation. The combination of a pyrimidinyl C-ring and a methylcyclohexyl element resulted in lead molecule 28, which exhibited ∼50-fold selectivity. Compared to a nonselective BACE1/2 inhibitor, 28 showed significantly less inhibition of PMEL processing in human melanocytes, indicating good functional selectivity of this inhibitor class.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inhibidores de Proteasas / Ácido Aspártico Endopeptidasas / Secretasas de la Proteína Precursora del Amiloide Límite: Animals / Female / Humans / Male Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2018 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inhibidores de Proteasas / Ácido Aspártico Endopeptidasas / Secretasas de la Proteína Precursora del Amiloide Límite: Animals / Female / Humans / Male Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2018 Tipo del documento: Article País de afiliación: Suecia